Extraordinary advances are happening at the Mount Sinai Health System, and we want you to be among the first to know. Mount Sinai Physician’s Channel will show you some of the innovative procedures, developments in patient care, and complex cases that are being handled in our world-class facilities. We invite you to come back often to stay on top of what’s new in your specific field.
Featured Items
New Content
New Study Identifies Genetic Changes in Brain Development That May Contribute to Schizophrenia
A collaborative study between researchers at the Icahn School of Medicine at Mount Sinai and Harvard Medical School has identified genetic mutations that occur during brain development and may contribute to the development of schizophrenia.
Changing the Lives of Patients with Rare Diseases
Mount Sinai’s Department of Genetics and Genomic Sciences has a long-standing history of pioneering treatments for rare diseases, bringing therapies from the lab to patients who previously had no options.
The Unexpected Link between Parkinson’s Disease and the Gut
The laboratory of Inga Peter, PhD, Vice Chair of the Mount Sinai Department of Genetics and Genomic Sciences, has uncovered a surprising link between inflammatory bowel disease (IBD) and Parkinson’s disease.
At the Forefront of Genomics Technology
Mount Sinai’s Center for Advanced Genomics Technology (CAGT) offers the latest in sequencing tools, driving innovation in both basic and translational research that will impact clinical care.
Unlocking the Secrets of the Microbiome
Researchers at Mount Sinai are making significant advances in understanding the role of the microbiome in health and disease.
The Next Frontier of Precision Medicine
Mount Sinai has joined the Clinical Proteomic Tumor Analysis Consortium (CPTAC), a national initiative aimed at advancing cancer treatment by integrating proteogenomics—analyzing the proteins encoded by cancer genes.
Tracking the Evolution of Pathogens
The Mount Sinai Pathogen Surveillance Program (PSP) is leading efforts to track the evolution of infectious diseases by sequencing over 25,000 bacteria and viruses isolated from patients within the health system.
Understanding the Genetics of Alzheimer’s Disease
Alison Goate, DPhil, Chair of the Department of Genetics and Genomic Sciences and Director of the Ronald M. Loeb Center for Alzheimer’s Disease, leads groundbreaking research on how genetic risk factors contribute to Alzheimer’s.
Building Models of Complex Diseases at Mount Sinai
The Mount Sinai Center for Transformative Disease Modeling is leading efforts to integrate big data and biological networks to uncover new therapeutic targets for complex diseases like Alzheimer’s, Parkinson’s, and cancer.
Register Today for the Second Annual Mount Sinai Women’s Health Forum
Wednesday, November 13, 2024 7:00 AM - 6:00 PM New York Academy of Medicine 1216 Fifth Avenue New York, NY 10029
The progression of atherosclerosis in people who have no symptoms of it is independently associated with the risk of dying from any cause, according to a new study led by researchers from Mount Sinai Fuster Heart Hospital, published September ...
New Insights Into Intellectual Disability Genetics Emerge at Mount Sinai
Researchers at the Icahn School of Medicine at Mount Sinai have published a pivotal study in Nature Genetics (DOI: 10.1038/s41588-024-01917-1) that sheds light on a novel genetic variant associated with intellectual capacities and educational outcomes.
A new four-year, $3.26 million grant from the National Institute of Neurological Disorders and Stroke (NINDS), a part of the National Institutes of Health (NIH), establishes the first Undiagnosed Diseases Network (UDN) site in the New York metropolitan area.
Mount Sinai Health System has announced the launch of its Center of Excellence for Gynecologic Cancer, which is part of The Tisch Cancer Institute.
Mount Sinai Health System and IBM Research today announced the launch of the Phenotypes Reimagined to Define Clinical Treatment and Outcome Research (PREDiCTOR) study.
The SGLT2 inhibitor empagliflozin confers kidney-protective benefits and can therefore be given safely and effectively to patients when they are hospitalized for acute myocardial infarction (MI), a Mount Sinai-led global team of researchers has shown.
Thickness Is Key to New Staging System for Pleural Mesothelioma
For patients with pleural mesothelioma, having a higher sum of maximum pleural thickness at three specific levels measured in the axial plane predicts worse survival. This finding informs the forthcoming ninth edition of the TNM Staging ...